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Abstract: Stem cell therapy and tissue engineering represent a forefront of current research 
in the treatment of heart disease. With these technologies, advancements are being made into 
therapies for acute ischemic myocardial injury and chronic, otherwise nonreversible, myocardial 
failure. The current clinical management of cardiac ischemia deals with reestablishing perfusion 
to the heart but not dealing with the irreversible damage caused by the occlusion or stenosis of 
the supplying vessels. The applications of these new technologies are not yet fully established 
as part of the management of cardiac diseases but will become so in the near future. The discus-
sion presented here reviews some of the pioneering works at this new frontier. Key results of 
allogeneic and autologous stem cell trials are presented, including the use of embryonic, bone 
marrow-derived, adipose-derived, and resident cardiac stem cells.
Keywords: stem cells, cardiomyocytes, cardiac surgery, heart failure, myocardial ischemia, 
heart, scaffolds, organoids, cell sheet and tissue engineering
Introduction
It is well known that cardiovascular disease is a main cause of morbidity and mor-
tality worldwide.1 Traditional medical and surgical therapies have had success in 
the treatment of many cardiovascular diseases, such as coronary artery disease and 
valvular diseases, but have had limited success in the therapy of damaged myo-
cardium. Acute ischemic myocardial damage and chronic myocardial failure have 
been challenging conditions for which to provide an adequate long-term prognosis, 
although a recent study by Beltrami et al,2 demonstrated the ability of cardiac cells 
(cardiomyocytes) to divide after the occurrence of myocardial infarction (MI), and 
reentering the human cell cycle, but that may not be enough to provide the needed 
quantity of cells to restore the damage; the common belief before that study was that 
myocytes are unable to divide depending on the interpretation of the scar formation 
after the infarction.
This aspect widens our perspective of the management approach – from being 
dependent solely on medical, percutaneous coronary intervention (PCI) and a surgical 
approach, to include a new side for management that includes the application of stem 
cell therapy – as these conditions have so far exceeded the reach of traditional medicine. 
The use of stem cells and tissue engineering has been tested in the laboratories and 
clinical trials as a potential solution for future treatment.
When engineering tissue for use as a cardiovascular therapy, there are three main 
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A “scaffold” is a substitute that provides a structural platform 
for a new cellular microenvironment that supports new tissue 
formation. It allows cell attachment, migration, differentia-
tion, and organization that can aid in delivering soluble and 
bound biochemical factors.3
Cell sources
The choice of cells to populate a scaffold depends on the 
purpose of the new tissue graft. The new cells will synthe-
size the bulk of the mass of a tissue matrix, and will form 
the integrating connections with existing native tissues. They 
also maintain tissue homeostasis in general and  provide 
various metabolic supports to other tissues and organs. 
Terminally differentiated cells have been used with variable 
degrees of success and there are some limitations to their 
use in tissue engineering, but stem cells, and more recently 
adult stem cells, have become the major players in most new 
tissue replacement strategies.4 Their favorable properties 
are being harnessed to drive most new tissue engineering 
processes.5
Signaling factors
Signaling factors can influence, and even direct, a new 
tissue’s phenotype. Their application has been learned from 
signals observed during native tissue formation and they 
have direct and indirect effects on cell metabolism, migra-
tion, and organization.3
Stem cell types used  
for cardiac repair
Xenogeneic cells from nonhuman species have limitations in 
therapeutic strategies due to significant differences in anti-
gens between species, potentially leading to graft rejection. 
Meanwhile, allogeneic cells from human donors are likely to 
have greater success after implantation. Allogeneic stem cells 
include umbilical cord-derived cells, fetal cardiomyocytes, 
and embryonic mesenchymal stem cells (EmSCs). These 
cells, however, are still potentially subjected to immune 
surveillance and rejection.
To eliminate the potential for allogeneic rejection, autolo-
gous cells from the same individual have become a central 
focus of stem cell research. This category of cells includes 
skeletal myoblasts, adipose-derived stem cells (AdSCs), resi-
dent cardiac stem cells (RCSCs) and bone marrow-derived 
(BMD) stem cells, such as CD34+ cells, induced pluripotent 
stem cells (iPSCs), mesenchymal stem cells (MSCs), mul-




Fetal cardiomyocytes have significant potential for integration 
and regeneration.6,7 However, there are concerns, including 
immunogenicity, malignant potential, ethical questions, as 
well as limited availability. For these reasons, other cell 
types have surpassed this source as likely candidates for use 
in cardiac regenerative therapy.
emSCs
EmSCs have broad potential to differentiate into cells from 
all three embryonic germ layers. In addition, intact cardio-
myocytes have been produced in vitro as well.8 However, 
there are concerns about the use of EmSCs, due to their 
association with teratoma formation in rodent models9 and 
concerns about their potential malignant transformation. 
Moreover, the ethical and legal issues surrounding the use 
of human EmSCs have obstructed further exploration and 
shifted the existing attention onto other alternative sources 
for stem cell therapy in cardiac repair.
Human umbilical cord blood-derived cells
Human umbilical cord blood-derived cells are presently used 
for repopulating bone marrow in patients treated for bone 
marrow illnesses such as acute leukemia. Human cord blood 
contains a big number of non-hematopoietic stem cells that 
show fewer class II human leukocyte antigens and appears not 
to trigger an immune response, thus dropping the risk of rejec-
tion. This reduced immunological activity provides a striking 
option for regenerative therapy.10 A significant reduction in 
infarct size has also been shown after intramyocardial injection 
of human cord blood derived cells in animal models.11
Autologous sources
AdSCs
AdSCs have been considered as a source of adult stem cells for 
cardiac repair. Adipose tissue includes a heterogeneous mixture 
of MSCs, hematopoietic stem cells, and EPCs. Consequently, 
the major clinical advantages of this type of cell is their avail-
ability, easy harvesting, and relatively low cost. Preclinical stud-
ies have shown that AdSCs are associated with improvement in 
ventricular function in animal models of MI. The mechanism of 
neoangiogenesis formation has hypothesized paracrine effects 
as a possible mechanism of action for AdSCs.12,13
Skeletal myoblasts
Skeletal myoblasts can be harvested by muscle biopsy from 
the individual and grafted to cardiac tissue. Preclinical ani-
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Cardiac tissue engineering and regeneration using cell-based therapy
myotubules, and improve cardiac function after transfer into 
infarcted myocardium.14 Clinical human trials such as the 
Myoblast Autologous Grafting in Ischemic Cardiomyopathy 
(MAGIC) trial and others have demonstrated that epicardial 
injection of skeletal myoblasts during coronary artery bypass 
graft (CABG) surgery is feasible with likely functional ben-
efits (see Table 1 for study summaries).15,16 A major limitation, 
however, is that they remain devoted to the skeletal muscle 
lineage and have been associated with arrhythmias due to 
separation of cardiomyocytes by islands of skeletal muscle 
cells, therefore interfering with the propagation of electrical 
potentials.15
BMD stem cells
BMD stem cells are widely studied due to their versatility 
and ease of collection. Of these, the most frequently tested 
adult stem cells are BMD mononuclear cells. Encouraging 
results have been reported in animal models of ischemic 
heart failure.17
iPSCs
“iPSCs” are autologous adult cells that can be converted into 
pluripotent cells. Through specific alterations, adult cells can 
be reprogrammed to express embryonic genes, allowing them 
to differentiate into tissues other than their specific lineage. 
Table 1 Clinical effects of cell therapy for acute or chronic heart failure with different types of stem cells
Trial Cell source Route of delivery Effect on LV function
TOPCARe-AMi77 BMDs and CPCs intracoronary No change
BOOST79 BMDs intracoronary Positive
RePAiR-AMi82 BMDs intracoronary Positive
ReGeNT83 BMDs intracoronary No significant change
MYSTAR84 BMDs intracoronary/intramyocardial Positive
SwiSS-AMi85 BMDs intracoronary No change
LeUveN-AMi200 BMDs intracoronary No change
ASTAMi80 BMDs intracoronary No change
FiNCeLL201 BMDs intracoronary Positive
HeBe202 BMDs intracoronary No change
TiMe203 BMDs intracoronary No change
Late-TiMe87 BMDs intracoronary No change
APOLLO STUDY70 AdSCs intracoronary Positive
PReCiSe89 AdSCs Transendocardial No change
TOPCARe-CHD92 BMDs or CPCs intracoronary No change
FOCUS-CCTRN204 BMDs Transendocardial No change
Dib et al16 Skeletal myoblasts Transepicardial Positive
MAGiC15 Skeletal myoblasts Transepicardial No change
SeiSMiC205 Skeletal myoblasts Transendocardial No change, with positive trend
CAuSMiC206 Skeletal myoblasts Transendocardial Positive
Stamm et al72 BMDs Transepicardial Positive
Ang et al207 BMDs Transepicardial/intracoronary No change
STAR-heart94 BMDs intracoronary Positive
TOPCARe-DCM95 BMDs intracoronary Positive
ACT34-CMi208 CPCs intramyocardial Positive
POSeiDON93 BMD Transendocardial No change
SCiPiO28 RCSCs intracoronary Positive
CADUCeUS88 Cardiospheres intracoronary No change
C-CURe209 RCSCs Transendocardial Positive
Abbreviations: ACT34-CMi, Autologous Cellular Therapy CD34 – Chronic Myocardial ischemia; AdSCs, adipose-derived stem cells; APOLLO, AdiPOse-derived Stem 
ceLLs in the treatment of patients with ST-elevation myOcardial infarction; ASTAMi, Autologous Stem-cell Transplantation in Acute Myocardial infarction; BMDs, bone 
marrow-derived stem cells; BOOST, BOne marrOw transfer to enhance ST-elevation infarct regeneration; C-CURe, Cardiopoietic stem Cell therapy in heart failURe; 
CADUCeUS, CArdiosphere-Derived aUtologous Stem Cells to reverse ventricUlar dySfunction; CAuSMiC, CAtheter-based delivery of aUtologous Skeletal Myoblasts for 
ischemic Cardiomyopathy; CPC, circulating progenitor cells; FiNCeLL, FiNnish stem CeLL trial; FOCUS-CCTRN, First Mononuclear Cells injected in the United States 
conducted by the CCTRN [Cardiovascular Cell Therapy Research Network]; HeBe, Multicenter, randomized trial of intracoronary infusion of autologous mononuclear 
bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention (PCi); LateTiMe, Use of Adult Autologous Stem Cells in 
Treating People 2 to 3 weeks after having a Heart Attack; LeUveN-AMi, Leuven acute myocardial infarction; Lv, left ventricular; MAGiC, Myoblast Autologous Grafting 
in ischemic Cardiomyopathy; MYSTAR, MYocardial STem cell Administration after acute myocardial infaRction; POSeiDON, Comparison of Allogeneic versus Autologous 
Bone Marrow-Derived Mesenchymal Stem Cells Delivered by Trans-endocardial injection in Patients with ischemic Cardiomyopathy; PReCiSe, AdiPose-deRived stem and 
Regenerative Cells in the Treatment of Patients with non revaScularizable ischemic myocardium; RCSCs, resident cardiac stem cells; ReGeNT, Myocardial ReGeNeraTion 
by intracoronary infusion of selected population of stem cells in acute myocardial infarction; RePAiR-AMi, Reinfusion of enriched Progenitor cells And infarct Remodeling in 
Acute Myocardial infarction; SCiPiO, Stem Cell infusion in Patients with ischemic cardiOmyopathy; SeiSMiC, Safety and effects of implanted (Autologous) Skeletal Myoblasts 
(MyoCell) Using an injection Catheter; STAR-heart, The acute and long-term effects of intracoronary Stem cell Transplantation in patients with chronic heARt failure; SwiSS-
AMi, Swiss Multicenter intracoronary Stem cells Study in Acute Myocardial infarction; TiMe, Timing in Myocardial infarction evaluation; TOPCARe-AMi, Transplantation of 
Progenitor Cells and Regeneration enhancement in Acute Myocardial infarction; TOPCARe-CHD, Trans-Coronary Transplantation of Functionally Competent BMD Stem 
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Interestingly, a recent publication has led to the discovery 
of a cardiac progenitor population of cells expressing both 
platelet-derived growth factor receptor-alpha and kinase 
insert domain receptor derived from human iPSCs that can 
give rise to smooth muscle cells (SMCs), cardiomyocytes, 
and vascular endothelial cells (ECs).18 Also, vascular ECs 
from human iPSCs can be attained from several distinct 
progenitor populations.
RCSCs
RCSCs have recently been discovered with great interest. 
Previously, the heart was considered to lack self-renewal 
capabilities as a terminally differentiated organ. Evidence 
has now shown, however, that the heart demonstrates con-
tinuous cell division following various injuries; for example, 
post-MI.2 Several studies have addressed, identified, and 
isolated RCSCs, which are capable of differentiating into 
multiple cell types, such as cardiomyocytes or vascular SMCs 
(VSMCs).19,20 Reduction in the infarct size and improvement 
of left ventricular (LV) function were noticed in rodent mod-
els of MI after RCSC culture and injection.21 These cells are 
an attractive option for cardiac repair. However, effective 
harvesting techniques need to be perfected (see Table 1 for 
study summaries).
The best-characterized and most well-studied RCSC 
population is c-kit+/Lin– cells, originally described in the 
rat heart.19 The c-kit+/Lin– RCSCs, isolated and expanded 
in culture, exhibit all the properties of induced stem cells. 
When injected into the injured myocardium, they were 
shown capable of restoring the cardiac pattern and function 
in various animal models of ischemic heart model, albeit to 
a variable extent.22–24 Human c-kit+ cells have also recently 
been tested as a potential therapy in patients suffering from 
ischemic cardiomyopathy with promising results.19,24–28
Origin, production, and purification 
of cardiac stem cells
Since 1960, different experiments and discoveries in the field 
of stem cells have been made. Emerging clinical application 
trials started to evolve in the past 15 years and include but 
are not limited to the study of cardiac regeneration.
embryologic development  
of stem cells in the heart
Different theories addressed the origin of stem cells in the 
heart. The origins of the cells in the heart may affect organ 
function, which implies that cells for tissue engineering 
and regenerative medicine should be selected cautiously. 
The myocardial cells in the adult heart originate from meso-
dermal precursors during the embryonic period of the heart’s 
growth. Signaling pathways orchestrate the formation of the 
first and second heart fields,29 which become cardiomyocytes, 
and the subsequent growth of the four-chambered heart from 
a linear heart tube.30,31 After the early framework for the heart 
is formed, some mesodermal cells from the proepicardium 
are enrolled to form the epicardium, the single layer of cells 
enveloping the heart.32
Next, in transition from an epithelial to mesenchymal 
layer, epicardial cells become migratory mesenchymal 
cells. These cells enter the underlying myocardium and dif-
ferentiate into VSMCs as well as fibroblasts of the vascular 
interstitium and adventitia.
While the origin of the coronary endothelium is contro-
versial, the present understanding is that this endothelium 
has a well-defined progenitor population of SMCs and 
fibroblasts in the proepicardium.33,34 It is interesting that 
only after the main structure of the coronaries is estab-
lished do the ECs conquer the aorta and create the coronary 
circulation.35
Differentiation of stem cells  
into cardiomyocytes
The derivation of cardiomyocytes from human pluripotent 
stem cells follows a distinct developmental lineage through-
out mesoderm induction. There has been a recent increase in 
the understanding of this process since the ability to derive 
cardiomyocytes from human EmSCs and iPSCs has driven 
a transition from using pluripotent cells to form cardiomyo-
cytes for tissue engineering36 (summarized in Figure 1). The 
use of cardiomyocytes was first introduced when neonatal 
rat ventricular cardiomyocytes, which were developed for 
cardiac tissue engineering,34 were seeded into gel-foam and 
implanted onto an infarcted adult rat heart.35
Differentiation protocols for human EmSCs to car-
diomyocytes involve adding bone morphogenetic protein 4 
(BMP4) and recombinant human activin A to induce the 
cardiac mesoderm to reproduce the main foundations of 
embryonic development.18,37,38 Laflamme et al18 produced 
cardiomyocyte populations with over 50% cardiac purity 
(consisting of nodal cells, ventricular cells, and atrial cells). 
In this protocol, they induced endogenous expression of 
recognized Wnt ligands, and after mesodermal Wnt induc-
tion, successful cardiac differentiation requires subsequent 
inhibition of this pathway.39 This biphasic signaling profile, 
which normally occurs during development,40,41 offers an 
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Cardiac tissue engineering and regeneration using cell-based therapy
in different human EmSC and human iPSC lines and can be 
boosted by the addition of exogenous Wnt3a followed by 
inhibition of Wnt signaling with dickkopf-related protein 1 
(DKK1) to increase cardiogenesis.39
Yang et al37 developed a different approach mimicking the 
three-dimensional (3D) setting of an evolving embryo using 
small cell groups called “embryoid bodies”. These cells are 
exposed to basic fibroblast growth factor (bFGF), activin A, 
BMP4, vascular endothelial growth factor (VEGF), and, after 
mesodermal induction, DKK1 in a hypoxic environment for 
10–12 days. A positive cardiovascular progenitor population 
expressing kinase insert domain receptor and platelet-derived 
growth factor receptor-alpha could be isolated on the 4th day, 
which revealed a differentiation of greater than 50% cardiac 
troponin T (cTnT)+ cardiomyocytes in multiple lines of 
human EmSC and human iPSCs.33 Progenitor cardiovascular 
cells derived using this protocol also give rise to low levels 
of ECs (CD31+), fibroblasts (discoidin domain receptor 2 
[DDR2]+), and VSMCs.
Another approach used the glycogen synthase kinase 3 
(GSK3) inhibitor to activate Wnt/β-catenin signaling and 
mesoderm differentiation, which yielded high levels of car-
diogenesis to produce greater than 80% cardiomyocytes.42
An alternative approach uses transdifferentiation and 
reprogramming of fibroblasts directly into cardiomyocytes 
at the in vivo stage, using gene therapy, avoiding the pluri-
potent stage.43,44 However, reproducing this high-yield work 
has proven to be a challenge,45 with very few transduced 
cells demonstrating contractile activity and several of 
these cells demonstrating only a partially reprogrammed, 
cardiomyocyte-like phenotype.46 This approach, though inef-
ficient at this time, will is likely to have potential in the future 
as therapy for patients who are not surgical candidates for 
revascularization using tissue-engineered replacement.
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Cardiac purity after differentiation
Once differentiation has been achieved, there are several 
strategies to improve the yield and the purity of the tissue 
sample. One proposed protocol involved Percoll density 
gradient centrifugation.18 This, however, reveled an injury 
to the cardiomyocytes and low survival rate at transplanta-
tion stage. Since then, multiple studies have used different 
strategies using genetic selection in which a cardiac-specific 
agent drives expression of an antibiotic-resistance gene, 
permitting cardiomyocytes to last while other cell types 
are lost.47–49 Cell-sorting techniques have been developed 
for cardiac-specific surface markers including vascular cell 
adhesion molecule (VCAM1)50 and signal regulatory protein 
alpha (SIRPA).51
Another strategy used involved culturing cells in a lactate-
rich medium that would eradicate or kill the cells that do not 
have enough mitochondria to survive (which most of the time 
are the non cardiac cells). 100% purity is hard to achieve. 
It has been reported that usage of unsorted cardiomyocytes 
with purities greater than 50% does not result in the forma-
tion of teratomas in animal model (rodent) studies,18 though 
occasional epithelial cysts have been detected.53 These results 
are promising and imply that practically high-purity human 
EmSC- and iPSC-derived cardiomyocytes can be developed 
for clinical usage (summarized in Figure 1).
Cell-based therapy for heart failure
The treatment of post-MI heart failure remains an important 
and difficult task due to the high prevalence of post-MI heart 
failure and low levels of success with traditional medical 
and surgical therapies.54 An evolving strategy for the treat-
ment of advanced ischemic cardiomyopathy is regenerative 
medicine. This involves the transplantation of pluripotent 
progenitor cells into the area of the infarcted myocardium 
with the expectancy of new functioning myocyte and vascular 
cell production.
The adult mammalian heart has been traditionally con-
sidered as a post-mitotic organ without intrinsic capacity for 
regeneration. Clinically, it behaves in this manner, with little 
recovery after ischemic damage. New understandings of cell 
biology, however, have caused a shift in such opinions and 
introduced a new avenue for potential therapy. Several reports 
have shown new cardiomyocyte cell-cycle production rang-
ing from 0.0005% to 3% in normal adult hearts,55–57 and the 
dating of adult hearts with 14C has also concluded that during 
a lifetime the human heart renews approximately 50% of its 
myocytes.58 For these reasons, animal experiments have been 
performed and the interest generated from these experiments 
has led to clinical trials to evaluate stem cells as therapy for 
damaged adult human hearts.59
Myocardial regeneration with  
allogeneic stem cell therapy
Allogeneic cells can be grown in large quantities in advance, 
stored before their use, and made available at short notice, 
which make them a suitable option for highly prevalent diseases 
and will permit their use soon after an acute insult to either 
prevent or diminish pathological remodeling of the heart.
As yet unanswered questions about the use of allogeneic 
stem cells in the treatment of patients with acute myocar-
dial injury need to be addressed, including what method of 
delivery is best for cell administration and what is the best 
cell population to deliver.
To be widely available and compatible with the cur-
rent clinical standard of care for acute myocardial injury, 
an intracoronary method for delivery at the time of the 
primary revascularization is feasible. Catheter-based direct 
myocardial injection during revascularization surgery is 
also realistic.
For choice of cell populations, MSCs have been tested. 
These cells secrete a broad range of favorable cytokines. 
However, they also secrete factors that negatively modulate 
cardiomyocyte apoptosis, inflammation, scar formation, 
and pathological remodeling, as described by Ranganath 
et al.60 Also, only approximately 3%–4% of the cells 
delivered by intracoronary technique are retained in the 
myocardium, as reported by Dauwe and Janssens,61 as well 
as Teng et al,62 and MSCs can clump together, becoming 
entrapped in the microvasculature and obstructing entry 
into the myocardium.
Groups of allogeneic cell types in small aggregates known 
as “cardiospheres” have also been tested for therapy in a 
rat module of infarcted hearts.63 Allogeneic cardiosphere-
derived cell (CDC) transplantation resulted in an improve-
ment in fractional area change (12%), ejection fraction (EF; 
20%), and fractional shortening (10%), which was sustained 
for at least 6 months. Also, allogeneic CDCs stimulated 
regeneration through endogenous mechanisms, such as 
increased myocardial VEGF, insulin-like growth factor 1, 
and hepatocyte growth factor, and the recruitment of c-kit+ 
angiogenesis.63
One promising cell type to undergo testing for cell therapy 
is the RCSC, which has advanced beyond more primitive stem 
cells into a definite cardiac lineage but has not yet terminally 
differentiated or matured. Unlike other cell types such as 
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Cardiac tissue engineering and regeneration using cell-based therapy
et al64 and Hofmann et al,65 RCSCs have a high tropism for 
the myocardium. When administered through the systemic 
circulation, the majority of RCSCs home to and nest in the 
damaged myocardium.66
Under appropriate conditions it is possible to replicate 
and expand RCSCs up to 1×1011 cells without noticeable 
alteration of karyotype, loss of differentiating properties, 
or the phenotype of the differentiated progeny.67 These cells 
produce a range of beneficial pro-survival, anti-inflamma-
tory, and cardiovascular regenerative growth factors, such 
as insulin-like growth factor 1, hepatocyte growth factor, 
activins, transforming growth factor-beta 1, and neuregulin-1, 
among others.68
It is postulated that it is because of the secretion of these 
regenerative factors that allogeneic stem cell therapy is 
successful. The factors produced by the allogeneic cells may 
stimulate endogenous stem cells of the target tissue while the 
transplanted cells themselves may survive only transiently. Thus, 
they might not directly participate in the production of progeny 
that contribute to the regenerated tissue. As a result, although the 
therapeutic cells are allogeneic, a lasting regenerative response 
may be autologous, carried out by host RCSCs.69
Myocardial regeneration  
with autologous stem cell therapy
Notwithstanding the values of autologous therapy, autologous 
cells require time for preparation and are not suited for highly 
prevalent diseases. A study done using an intracoronary infu-
sion of AdSCs within hours of percutaneous revasculariza-
tion in patients presenting with acute MI showed improved 
left ventricular ejection fraction (LVEF) with reduced scar 
formation.70
Meanwhile, intracoronary injection of autologous BMD 
stem cells in patients with chronic heart failure had been 
shown to result in a corresponding 15% improvement in EF 
and a 30% reduction in infarct size.71 Direct myocardial injec-
tion of CD133+ BMD stem cells into infarct border zones led 
to an improvement in LVEF from 37% to 47%.72
Also, cardiac stem cells have been shown to differentiate 
into multiple cell types, including cardiac myocytes, SMCs, 
and ECs.19 Infusion of autologous Lin–/c-kit+ cardiac stem 
cells into patients with post-MI resulted in LVEF improve-
ment from 30.3% to 38.5%.28
In patients with refractory angina after conventional 
revascularization therapy, compelling evidence support-
ing stem cell therapy emerged from a randomized trial of 
catheter-based intramyocardial (endoventricular) injection 
of CD34+ progenitor cells, arranged following granulocyte 
colony stimulating factor-induced cell mobilization and 
“leukapheresis” (separation of white blood cells).73 It 
showed a trend in efficacy for endpoints such as fewer 
angina episodes, lowered nitroglycerin usage, improved 
exercise time, and improved functional class (as per the 
New York Heart Association Functional Classification) 
when compared with placebo. These results were similar 
to a recent trial (Efficacy and Safety of Targeted Intramyo-
cardial Delivery of Auto CD34+ Stem Cells for Improving 
Exercise Capacity in Subjects With Refractory Angina 
[RENEW] study).73,74 In another trial, when patients 
were injected with bone marrow mononuclear stem cells 
endocardially, a trend toward improvement in chronic 
ischemia refractory to medical treatment was shown. 
Although there was no significant difference.75 In conjunc-
tion with coronary arterial bypass grafting, another study 
showed that intramyocardial injection of high-dose BMD 
mononuclear cells yields improved results compared with 
CABG alone.76 When CD133+ cells are injected through 
the transepicardial route during coronary surgery, there 
has been an improved LVEF and perfusion at 6 months 
post-operatively.72
Clinical trials of cell therapy  
for heart failure
Many studies have addressed the efficacy of stem cell 
injection in the cardiac disease patient. Here, we mention 
some of these studies and divide them depending on the 
timeframe of the intervention (summarized in Figure 2 and 
Tables 1 and 2).
Acute heart failure
intervention within ,7 days
Transplantation of Progenitor Cells and Regeneration 
enhancement in Acute Myocardial infarction  
(TOPCARe-AMi)
This was a safety and feasibility trial targeting patients with 
acute MI successfully reperfused by stent implantation. They 
used an intracoronary infusion of circulating progenitor 
cells (CPCs) (approximately 245±72×106 Ficoll-separated, 
cultured CPCs) and bone marrow cells (approximately 
10±7×106 Ficoll-separated BMD cells) 4 days after the 
infarction. It showed a trend of improvement in regional 
wall motion in the infarcted zone and reduction of end-
systolic LV volume immediately after the injection as well 
as during the 4-month follow-up. The efficacy was similar 
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BOne marrOw transfer to enhance  
ST-elevation infarct regeneration (BOOST)
This study targeted patients who had acute MI and had stent 
implanted using PCI. They had a transfusion of a single dose 
of autologous bone marrow stem cells through intracoronary 
route. The number of cells used was approximately 2.5×109 
of unfractionated BMD cells. The results showed a slight 
improvement in LVEF of 7%, which was, however, not sus-
tained at 18 months.78,79
Autologous Stem-cell Transplantation in Acute  
Myocardial infarction (ASTAMi)
This trial targeted patients with acute ST-segment elevation 
myocardial infarction (STEMI). They harvested autologous 
bone marrow cells, which were delivered through intracoronary 
injections during PCI for stent implantation. The number of 
cells used was approximately 7×107 Ficoll-separated BMD 
stem cells. In this trial, there was no improvement in LVEF 




























Figure 2 Clinical trials of cell therapy for acute and chronic, ischemic and nonischemic heart failure.
Abbreviations: ASTAMi, Autologous Stem-cell Transplantation in Acute Myocardial infarction; BOOST, BOne marrOw transfer to enhance ST-elevation infarct regeneration; 
CADUCeUS, CArdiosphere-Derived aUtologous Stem Cells to reverse ventricUlar dySfunction; LateTiMe, Use of Adult Autologous Stem Cells in Treating People 2 to 3 weeks 
after having a Heart Attack; MYSTAR, MYocardial STem cell Administration after acute myocardial infaRction; POSeiDON, Comparison of Allogeneic versus Autologous Bone 
Marrow-Derived Mesenchymal Stem Cells Delivered by Trans-endocardial injection in Patients with ischemic Cardiomyopathy; PReCiSe, AdiPose-deRived stem and Regenerative 
Cells in the Treatment of Patients with non revaScularizable ischemic myocardium; ReGeNT, Myocardial ReGeNeraTion by intracoronary infusion of selected population of stem 
cells in acute myocardial infarction; RePAiR-AMi, Reinfusion of enriched Progenitor cells And infarct Remodeling in Acute Myocardial infarction; SCiPiO, Stem Cell infusion in 
Patients with ischemic cardiOmyopathy; STAR-heart, The acute and long-term effects of intracoronary Stem cell Transplantation in patients with chronic heARt failure; SwiSS-
AMi, Swiss Multicenter intracoronary Stem cells Study in Acute Myocardial infarction; TOPCARe-AMi, Transplantation of Progenitor Cells and Regeneration enhancement in 
Acute Myocardial infarction; TOPCARe-CHD, Trans-Coronary Transplantation of Functionally Competent BMD Stem Cells; TOPCARe-DCM, Selective intracoronary Bone 
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Cardiac tissue engineering and regeneration using cell-based therapy
Reinfusion of enriched Progenitor cells And infarct 
Remodeling in Acute Myocardial infarction (RePAiR-AMi)
This was a randomized and double-blinded study target-
ing patients who had PCI after acute MI. They divided the 
population into two groups receiving bone marrow cells versus 
placebo infusion. The total number of cells used was estimated 
to be 2.4×108. The initial 4 months’ result showed an increase 
in LVEF in the bone marrow group compared with in the 
Table 2 Cells number and purification methods
Trial Cell source (number of cells used) Separation/purification method




BOOST79 BMDs (2.5×109) Density gradient sedimentation, CD34+ flow cytometry
ASTAMi80 BMDs (7×107) Ficoll centrifugation
RePAiR-AMi82 BMDs (2.4×108) Ficoll centrifugation




MYSTAR84 BMDs e (1.56±0.40×109) 
BMDs L (1.55±0.44×109)
COBe® Spectra™ filter 
Fluorescence cell sorting




LateTiMe87 BMDs (150×106) Ficoll centrifugation 
Fluorescence cell sorting
PReCiSe89 AdSCs (42×106) Cytori Celution® device™
TOPCARe-CHD92 BMDs (214±98×106) Ficoll centrifugation
POSeiDON93 Allogenic/Autologous BMDs (20–100–200×106) Ficoll centrifugation
STAR-heart94 BMDs (6.6±3.3×107) Ficoll centrifugation, CD34+/CD133+
TOPCARe-DCM95 BMDs (259±135×106) Ficoll centrifugation
SCiPiO28 RCSCs (1 million) immunomagnetic sorting with human CD117
LeUveN-AMi200 BMDs (172–304×106) Ficoll centrifugation
FiNCeLL201 BMDs (360×106) Ficoll centrifugation
HeBe202 BMDs (296±164×106) 
Blood (287±137×106)
Lymphoprep density centrifugation
TiMe203 BMDs (150×106) Ficoll centrifugation
APOLLO70 AdSCs (17.4±4.1×106) Cytori Celution® device™
FOCUS-CCTRN204 BMDs (100×106) Ficoll centrifugation, flow cytometry CD34, 133
Dib et al16 SMs (1–3×108) Anti-CD56 antibody staining
MAGiC15 SMs (400–800×106) Flow cytometry CD56+ cells
SeiSMiC205 SMs (586±193×106) Flow cytometry CD56+ cells
CAuSMiC206 SMs (2×105) Anti-CD56 monoclonal antibodies
Stamm et al72 BMDs (5.8×106) Magnetic separation with ferrite-conjugated antibody
Ang et al207 BMDs iM (84±56×106) 
BMDs iC (115±73×106) 
CD34+/CD117+ iM (142±166×103) 
CD34+/CD117+ iC (254±254×103)
Lymphoprep™ density centrifugation
ACT34-CMi208 MSCs (1–5×105)/kg CD34+ fluorescence sorting
CADUCeUS88 Cardiospheres (12.5–25.0×106) 95% positive CD105
C-CURe209 BMDs (600–1,200×106) PCR of CD34, FABP4, SOX9, osteocalcin, and nestin 
(exposed vs nonexposed to cardiac GF cocktail)
Abbreviations: ACT34-CMi, Autologous Cellular Therapy CD34 – Chronic Myocardial ischemia; AdSCs, adipose-derived stem cells; APOLLO, AdiPOse-derived Stem ceLLs 
in the treatment of patients with ST-elevation myOcardial infarction; ASTAMi, Autologous Stem-cell Transplantation in Acute Myocardial infarction; BMDs, bone marrow-
derived stem cells; BOOST, BOne marrOw transfer to enhance ST-elevation infarct regeneration; C-CURe, Cardiopoietic stem Cell therapy in heart failURe; CADUCeUS, 
CArdiosphere-Derived aUtologous Stem Cells to reverse ventricUlar dySfunction; CAuSMiC, CAtheter-based delivery of aUtologous Skeletal Myoblasts for ischemic 
Cardiomyopathy; CPCs, circulating progenitor cells; e, early; FiNCeLL, FiNnish stem CeLL trial; FOCUS-CCTRN, First Mononuclear Cells injected in the United States 
conducted by the CCTRN [Cardiovascular Cell Therapy Research Network]; GF, growth factors; iC, intramyo cardial; iM, intra muscular; HeBe, Multicenter, randomized trial 
of intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention (PCi); KDR, 
kinase insert domain receptor; L, late; LateTiMe, Use of Adult Autologous Stem Cells in Treating People 2 to 3 weeks after having a Heart Attack; LeUveN-AMi, LeUveN- 
Acute Myocardial infarction; MAGiC, Myoblast Autologous Grafting in ischemic Cardiomyopathy; MSCs, mesenchymal stem cells; MYSTAR, MYocardial STem cell Administration 
after acute myocardial infaRction; PCR, polymer chain reaction; POSeiDON, Comparison of Allogeneic versus Autologous Bone Marrow-Derived Mesenchymal Stem Cells 
Delivered by Trans-endocardial injection in Patients with ischemic Cardiomyopathy; PReCiSe, AdiPose-deRived stem and Regenerative Cells in the Treatment of Patients with 
non revaScularizable ischemic myocardium; ReGeNT, Myocardial ReGeNeraTion by intracoronary infusion of selected population of stem cells in acute myocardial infarction; 
RePAiR-AMi, Reinfusion of enriched Progenitor cells And infarct Remodeling in Acute Myocardial infarction; RCSCs, resident stem cells; SCiPiO, Stem Cell infusion in Patients 
with ischemic cardiOmyopathy; SeiSMiC, Safety and effects of implanted (Autologous) Skeletal Myoblasts (MyoCell) Using an injection Catheter; SMs, skeletal myoblasts; STAR-
heart, The acute and long-term effects of intracoronary Stem cell Transplantation in patients with chronic heARt failure; SwiSS-AMi, Swiss Multicenter intracoronary Stem cells 
Study in Acute Myocardial infarction; TiMe, Timing in Myocardial infarction evaluation; TOPCARe-AMi, Transplantation of Progenitor Cells and Regeneration enhancement in 
Acute Myocardial infarction; TOPCARe-CHD, Trans-Coronary Transplantation of Functionally Competent BMD Stem Cells; TOPCARe-DCM, Selective intracoronary Bone 











































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





placebo group. At the 2-year follow-up, cell-treated patients in 
this trial had had fewer myocardial ischemias and there were 
fewer patients who met the combined endpoint of death, MI, 
or need for revascularization. Although the results were not 
statistically significant, there was a trend toward sustained 
improvement in EF and LV end-systolic volume.81,82
Myocardial ReGeNeraTion by intracoronary  
infusion of selected population of stem cells  
in acute myocardial infarction (ReGeNT)
REGENT was a randomized, multicenter study targeting 
patients with acute STEMI within 12 hours of the symptoms, 
to assess the myocardial regeneration by intracoronary infu-
sion of selected populations of BMD stem cells. They used 
autologous BMD cells and divided them into three groups: 
selected CD34+ group (median number of cells 1.90×106), 
nonselected bone marrow cell group (median number of cells 
1.78×108), and placebo group. The treatment with BMD stem 
cells did not lead to a significant improvement in LVEF or LV 
volumes. However, there was a trend in favor of cell therapy in 
patients with the most severely impaired LVEF and prolonged 
periods between symptoms and revascularization.83
intervention within .7 days
MYocardial STem cell Administration after  
acute myocardial infaRction (MYSTAR)
The hypothesis relied on, is the injected stem cells homing 
which will be ideal 21 days after the incident of MI but not 
later than 42 days. They used autologous bone marrow stem 
cells by intracoronary and intramyocardial injections at two 
different timings. Patients were divided into four groups: 
early intracoronary nonselected BMD stem cells (between 21 
and 42 days), early combined intracoronary with intramyocar-
dial BMD stem cells, late (3 months) intracoronary injection, 
and late combined injections. The mean number of injected 
cells in the early group and late group was 1.56±0.40×109 
and 1.55±0.44×109, respectively. The results showed that the 
early and late delivery of cells induced mild, but not clinically 
relevant, improvements. There was a reduction in infarct size 
and an improvement in LVEF at both 3 months and 9 to 12 
months after acute myocardial ischemia. The main improve-
ments in the early and late groups were an estimated 3.5% and 
3.9%, respectively, improvement in LVEF, as well as a 3.5% 
and 3.4%, respectively, improvement in infarct size.84
Swiss Multicenter intracoronary Stem cells Study  
in Acute Myocardial infarction (SwiSS-AMi)
In this trial, BMD mononuclear stem cells were injected 
through the intracoronary route for patients who had STEMI, 
received a successful PCI intervention within 24 hours, and 
had an EF of less than 45%. They used an intracoronary 
injection of an estimated 153×106 and 139.5×106 of BMD 
stem cells in the early group (5–7 days) and in the late group 
(3–4 weeks), respectively. It showed that the infusion of BMD 
stem cells, either at 5–7 days or 3–4 weeks after acute MI 
did not improve LV function at 4 months.85
Use of Adult Autologous Stem Cells in Treating People 2 
to 3 weeks after having a Heart Attack (LateTiMe)
This trial evaluated the use of bone marrow mononuclear 
(BMD) stem cells with infusion at 2 to 3 weeks after acute 
anterior-wall MI versus placebo in patients with EF less than 
45% successfully treated with primary PCI. Single intracoro-
nary infusion of 150×106 of autologous BMD stem cells was 
injected within 12 hours of aspiration and cell preparation. 
The results showed no substantial improvement in LVEF 
measured after 6 months.86,87
CArdiosphere-Derived aUtologous Stem Cells  
to reverse ventricUlar dySfunction (CADUCeUS)
This was a randomized prospective trial targeting patients 
within 2–4 weeks of acute MI with an LVEF of 25%–45%. 
Cells were obtained from the right ventricular endocardium 
through biopsy. Patients received either a low dose (12.5×106) 
or a high dose (25×106) of cells versus a control group (which 
received no cells). The cells were introduced through the 
intracoronary route using an angioplasty catheter over a 
period of 15 minutes. This study was done to assess the safety 
of CDCs. There was a significant decrease in the scar size 
and increase in viable myocardium at 6 and 12 months in 
the treatment group compared with in the control group, but 
there was no significant difference between the two groups 
at 6 months in terms of EF improvement.88
Chronic heart failure
AdiPose-deRived stem and Regenerative Cells  
in the Treatment of Patients with non 
revaScularizable ischemic myocardium (PReCiSe)
PRECISE was a randomized clinical trial of AdSCs for 
patients with no revascularization option by either surgery 
or PCI. The autologous AdSCs were harvested by liposuction 
and the mean of the total number of cells used was 42×106 in 
the treatment group. This trial, which had an AdSCs group 
versus a placebo group, showed that harvesting and transen-
docardial injection of AdSCs are safe and feasible. Also, the 
treatment appeared to result in scar stabilization.89 However, 
data preceding this trial, by Perin et al, explored the transen-
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Cardiac tissue engineering and regeneration using cell-based therapy
ischemic cardiomyopathy and a mean LVEF of less than 
40%.90 There was no major improvement in LVEF at 6 or 
12 months in the treated group when  compared with control 
subjects. There was, however, a substantial improvement in 
exercise capacity, as well as ischemic burden, as measured 
by single-photon emission computed tomography (SPECT), 
found at 6 and 12 months.91
Transplantation of progenitor cells and recovery 
of left ventricular function in patients with chronic 
ischemic heart disease (TOPCARe-CHD)
This study targeted patients with an MI of more than 
3 months who were stable on medical therapy since the attack. 
Autologous BMD stem cells (mean number of 214±98×106) 
were injected through the intracoronary route. The study 
found that the treatment was associated with a reduction 
in natriuretic peptide serum levels (as natriuretic peptide 
serum levels are a solid marker for chronic heart failure) 
and improved the survival of patients with chronic heart 
failure post-MI.92
Percutaneous stem cell injection delivery effects on 
neomyogenesis: Comparison of Allogeneic versus 
Autologous Bone Marrow-Derived Mesenchymal 
Stem Cells Delivered by Trans-endocardial 
injection in Patients with ischemic Cardiomyopathy 
(POSeiDON)
This trial targeted patients with ischemic cardiomyopathy 
with EF of less than 50%. It compared autologous (extracted 
by bone marrow aspiration) and allogenic (extracted by bone 
marrow aspiration from healthy donors) MSCs. The research-
ers divided the population into three groups according to the 
number of infused cells: 20×106 for the first group, 100×106 
for the second group, and 200×106 for the third group. 
 Treatment was associated with lower rates of treatment-
emergent serious adverse effects, including immunologic 
reactions. MSC injection favorably affected patient quality 
of life, functional capacity, and ventricular remodeling.93
The acute and long-term effects of intracoronary 
Stem cell Transplantation in patients with chronic 
heARt failure (STAR-heart)
This study included a large group of patients with chronic 
ischemic heart failure within a time interval of 8.5±3.2 years 
between the infarct intervention and the admission to the 
clinical care. The study evaluated autologous BMD stem 
cells in patients with an LVEF of 35% or less and a remote 
history of MI. During this unblinded study, patients who 
refused cell therapy served as controls. The BMD stem 
cells were delivered into the infarct-related coronary artery 
through the intracoronary route and the estimated number 
of injected cells was 6.6±3.3×107. At 3 months, the treated 
group had had substantial improvements in cardiac index 
and calculated LVEF with an increase of almost 7%. There 
was also a drop in New York Heart Association class and in 
both end-systolic (≈15 mL) and end-diastolic (≈10 mL) ven-
tricular volumes. These improvements persisted at 12 and 60 
months after treatment, while no changes were noted in the 
control group. Also, the mortality rate of the treated group 
was remarkably lower than that of the control group (0.75% 
vs 3.68% per year). This trial provided the first long-term 
evidence that cell therapy can considerably affect mortality 
in heart failure patients.94
Stem Cell infusion in Patients with  
ischemic cardiOmyopathy (SCiPiO)
SCIPIO was the first randomized, open-label, Phase I clini-
cal trial in humans to evaluate autologous c–/kit+ RCSCs in 
patients with ischemic heart failure (LVEF equal to or less 
than 40%) at an average of 3.7 years post-MI. RCSCs were 
harvested from the right atrial appendage during CABG in 
33 patients (20 RCSC-treated vs 13 control subjects), with 
1×106 cells injected per patient. The RCSC-treated patients 
received an intracoronary infusion of cells at a mean of 
113 days after CABG. In the treated group, cardiac magnetic 
resonance imaging showed an increase in LVEF at 4 months 
(from 27.5%±1.6% to 35.1%±2.4% [P=0.004, n=8]) and 
at 12 months (41.2%±4.5% [P=0.013, n=5]). Infarct size, 
measured as late gadolinium enhancement by perfusion 
magnetic resonance imaging, decreased by −9.8±3.5 g after 
RCSCs infusion at 12 months in six patients who completed 
1-year follow-up. In the treated group, the LV infarcted mass 
decreased by −14.7±3.9 g and LV non-infarcted mass increased 
by +31.5±11.0 g at 12 months’ follow-up. The study concluded 
that the improvements in LVEF, decrease in infarcted LV mass, 
and increase in non-infarcted LV mass seen at 4 months and 
persisting for up to 12 months in a subgroup of patients were 
consistent with cardiac regeneration.27
Chronic nonischemic heart failure
Transplantation of progenitor cells and recovery of 
left ventricular function in patients with nonischemic 
dilatative cardiomyopathy (TOPCARe-DCM)
This trial targeted patients who had nonischemic dilated 
cardiomyopathy with an EF of less than 40% and LV end-
diastolic diameter of more than 60 mm who were stable for 
at least 6 months of medical therapy. The patients received 
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researchers used intracoronary infusion by PCI. The results 
of this trial were correlated with improvements in cardiac 
contractility and intracoronary circulation flow in patients with 
dilated cardiomyopathy, as well as a significant improvement 
in natriuretic peptide serum levels, although the latter was 
noticed after the 1-year follow-up but not before.95
Cardiac tissue engineering
Cardiac muscles, present in the pericardium, heart walls, and 
valves, form a dense network of striated and cross-linked 
cells. The muscle contains sarcomeres with sliding filaments 
of actin and myosin. The electrical and mechanical gap junc-
tions permit the heart to contract and relax in a coordinated 
fashion and conduct these impulses throughout the heart 
walls through the arteries and ventricles.96
The major diseases originating from cardiac muscles include 
MI, arrhythmias, ventricular dilatation, valvular diseases, and 
heart failure. It has been reported that the lack of donor organs, 
scar tissue formation, calcification of grafts, degradation, and 
inflammation of the affected tissue microenvironment are the 
most common problems associated with cardiac diseases. 
To overcome these hurdles, cardiac tissue engineering aims 
at assembling tissue constructs that can restore basic cardiac 
function by incorporating cellular components within scaf-
folds which in turn provide a framework of optimal structural, 
mechanical, and electrophysiological properties.97,98
Initially, cellular therapy involved the injection of “naked” 
cells into the site of injury, and although this technique has 
shown some promise in experiments,80,90 low cellular reten-
tion and engraftment rate limits its potential use for complete 
restoration of cardiac function.18,99,100
Recently, much emphasis has been placed on tissue 
engineering methods that mimic the biological and biome-
























































Figure 3 Biomimetic scaffolds
Notes: (A) Synthesis of biomatrix: fibroblasts isolated from samples of adult human heart were cultured in confluent state allowing for extracellular matrix (ECM) deposition 
in vitro. Representative image obtained by immunofluorescent labeling of actin filaments (red), cell nuclei (blue), and fibronectin (green). (B) Decellularization of biomatrix: 
after nonenzymatic removal of fibroblasts, ECM was observed under fluorescence microscope. Its composition was revealed by indirect immunofluorescent staining of 
representative ECM proteins: collagen IV (red), laminin (green), fibronectin (blue), and tenascin-C (yellow). (C) immunoblotting of the decellularized biomatrix further 
confirmed the presence of these ECM-specific components in the biomatrix. Adapted from: Clotilde Castaldo, Franca Di Meglio, Rita Miraglia, et al., “Cardiac Fibroblast-
Derived extracellular Matrix (Biomatrix) as a Model for the Studies of Cardiac Primitive Cell Biological Properties in Normal and Pathological Adult Human Heart,” BioMed 
Research International, vol. 2013, Article iD 352370, 7 pages, 2013. doi:10.1155/2013/352370.210 (D) Decellularization of embryonic cardiac tissue and recellularization with 
e16.5 ventricular cells. The constructs create a favorable microenvironment for the cells to integrate and migrate on the scaffold. Macroscopic appearance of the supporting 
matrix changed from translucent to opaque following cell inclusion into the construct. This was further confirmed by hematoxylin and eosin (H&E) and toluidine blue staining 
of the reseeded scaffolds, revealing a highly cellular environment on the host matrix. Collagen structures also became more physically compact after incubation of the scaffold 
with the cells, as shown by electron microscopy (EM). Adapted from Cree Chamberland, Almudena Martinez-Fernandez, Rosanna Beraldi, and Timothy J. Nelson, “Embryonic 
Decellularized Cardiac Scaffold Supports embryonic Stem Cell Differentiation to Produce Beating Cardiac Tissue,” ISRN Stem Cells, vol. 2014, Article iD 625164, 10 pages, 
2014. doi:10.1155/2014/625164.211
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Cardiac tissue engineering and regeneration using cell-based therapy
maintain transplanted cell function and survival. The three 
most common methods being investigated in this regard are 
biomimetic scaffolds, decellularized tissue scaffolds, and 
scaffold-free constructs.
Biomimetic scaffolds
Biomimetic scaffolds are made of either natural or synthetic 
polymers or a hybrid natural/synthetic copolymer. Natural 
polymers (as seen in Figure 3A), such as collagen,4,101 
fibrin,102 alginate,103 Matrigel®,104 chitosan,105 and hyaluronic 
acid106 are biodegradable protein and polysaccharide mol-
ecules with a similar structure to the native component of 
the tissue extracellular matrix (ECM), making them more 
biocompatible and less immunogenic than synthetic poly-
mers with a higher capacity for cell adhesion and influence 
on various cellular functions.106 The disadvantage of using 
natural polymer-based scaffolds is their limited mechanical 
and biodegradable properties that are not easily tailored.
On the other hand, synthetic polymers used for cardiac 
tissue engineering, such as polyethylene glycol, polyhydroxy-
ethylmethacrylate, polylactide-glycolic acid, and poly(N-
isopropylacrylamide), are easily tailored with predictable 
mechanical and chemical properties, but they may elicit an 
inflammatory response that might affect cell survival.106–109
In general, biomimetic scaffolds should be non-immu-
nogenic and mechanically stable, mimic cardiac tissue 
flexibility, allow physiological electrical propagation, allow 
sufficient oxygen and nutrient delivery to cells, and have 
a degradation rate appropriate to the rate of native ECM 
replacement.97,110
Biomimetic scaffolds are used alone, as acellular scaf-
folds, or in combination with cells.111–114 Preparation and 
delivery can be further divided into either in vitro culture 
with cells to produce 3D engineered cardiac tissues115–117 
or in vivo injection either directly in situ or with minimally 
invasive through catheter-based systems.103,118
The pathological process that leads to heart failure post-MI 
includes an initial inflammatory response, loss of cardiomyo-
cytes, and loss of the ECM, which leads to scar formation and 
ventricular wall thinning.110,119,120 Injecting acellular biomimetic 
scaffolds at the site of MI, with or without bioactive molecules, 
provides structural mechanical support,121,122 decreases the 
amount of fibrosis and ventricular dilation, and promotes 
angiogenesis and the recruitment of native stem cells.101
Scaffolds combined with cells form environmental substrates 
to replace the ECM and enhances the retention and survival of 
the transplanted cells, with one study reporting the increased 
early survival and retention of cardiomyoblasts in collagen 
scaffolds transplanted into rats in which MI was induced com-
pared with cardiomyoblasts in saline suspension.123
Selection of the cell type, scaffold material, and incor-
poration of bioactive molecules and bioreactors should be 
considered in constructing the optimal biomimetic scaffolds 
for treating cardiac diseases. “Bioreactors” are defined as 
specialized chambers designed to culture tissue-engineered 
constructs under controlled conditions.124,125 They have been 
developed to provide electrical and/or mechanical stimulation 
during tissue culture in order to promote uniform cellular 
distribution inside scaffolds, support the structure forma-
tion of 3D scaffold constructs, provide adequate oxygen and 
nutrient supply during culture, and help induce structural and 
functional cell maturation.126–128
For instance, it was found that electrical stimulation 
of neonatal rat myocyte in a collagen scaffold enhanced 
the conductive and contractile properties of the construct, 
increased cell alignment, and caused phenotypic changes 
resembling more mature myocytes compared with the non-
stimulated scaffold.129
Recent advancements in nanomaterial science have fur-
ther increased the efficiency of scaffolds. Davis et al used 
self-assembling peptides that rapidly form nanofibers and 
form a 3D scaffold at physiological pH and osmolarity.130 
After injecting these peptides and the formation of the scaf-
fold onto the free LV wall of adult male mice, the scaffold 
promoted the recruitment of endogenous endothelial and 
SMCs, and when compared with Matrigel scaffolds, fewer 
ECs were seen and they were localized around the edges. 
Furthermore, injecting neonatal mice cardiomyocytes with 
these self-assembling peptides resulted in the survival of 
these cells and the recruitment of endogenous cells that 
stained positively for myocyte progenitor markers.130
Also utilizing nanomaterial technology, Dvir et al incor-
porated gold nanowire within an alginate scaffold seeded with 
neonatal rat cardiomyocytes, which improved both electrical 
communication between cardiac cells and tissue formation, 
producing thicker tissue and better-aligned cells than cells 
in alginate scaffolds without the nanowires.131
Recently, there has been an interest in engineering 
cell-based cardiac pumps and tissue-engineered ventricles. 
Although technically challenging, such models can provide 
a potential concept for engineering a biological LV assist 
device or a biological drug pumping system. Furthermore, 
creating a hollow cardiac organoid structure can provide a 
flexible platform that can be adapted for the long-term study 
of cardiac pump function in vitro. Khait and Birla fabricated 











































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





a monolayer of cardiomyocytes with the resulting generation 
of intraluminal pressure,125 while Lee et al fabricated a cardiac 
organoid chamber using neonatal rat myocytes seeded in a 
collagen/Matrigel matrix then casted on a mold with a bal-
loon catheter to control chamber size. Spontaneous beating 
was observed after 7–10 days of culture and in a cryo-injury 
model of MI led to diminished global chamber pressure and 
decreased intrinsic pulse rate.132
Decellularization to build a new  
heart for transplantation
Whole-organ engineering is a promising field for the future 
of heart failure treatment.133 Since donor organs for trans-
plantation are a limited resource, creating replacement organs 
from cadaveric allogeneic or xenogeneic sources could reduce 
the need for living donors. Tissue engineering also avoids 
problems with synthetic materials or mechanical devices for 
heart failure, which are subject to foreign-body reactions and 
hardware or software malfunction. The shape and structure 
of biologic scaffolds are also superior to those of synthetic 
matrices, and their complexity is not reproducible.
Thus the use of decellularized matrices has the potential 
to overcome the need to artificially recreate the conditions for 
ECM deposition.134–138 Tissues used to prepare these biologic 
scaffolds are typically autogenic, allogeneic, or xenogeneic 
in origin.139 Thus the decellularization technique (as seen in 
Figure 3) is very crucial to the success of the treatment.
From a tissue engineering perspective, the major objec-
tives of decellularization are therefore to retain the structural 
integrity, composition and biological activity of the scaffold 
while completely removing the cellular and nuclear materials 
to eradicate any chance of unwanted immunological responses 
and other adverse side effects due to cross-presentation.140,141 
If performed properly, the decellularization technique can 
be applied not only to tissues, but also to entire organs.142 
Commonly used decellularized scaffolds in cardiac applica-
tions include adipose tissue, cartilages, and heart tissues of 
allogeneic, autologous,143–145 as well as xenogeneic origin.135,146 
Studies show rapid repopulation with cardiomyocytes in 
natural matrix obtained from porcine tissues.147–150
The optimum method of decellularization remains 
variable, as it depends on the specific requirements of the 
application, such as high density, high pressure, and stiff-
ness, which play vital roles in determining the method for 
decellularization.11,151 Chemical, enzymatic, microwave 
radiation,152 mechanical, and physical separations are 
the different methods used so far. Studies on the com-
parison of different techniques have been reported in the 
literature.153,154 It is known that a combination of physical, 
chemical, and enzymatic methods yields better results in 
the decellularization of both the whole organ and small 
tissues in cardiac applications.155,156 What is required for 
decellularization and recellularization is an organ to serve 
as a scaffold; a detergent, osmolar solution, or enzymatic 
solution to remove native cellular material; a choice of 
stem cells for repopulation; and a culture environment, 
or bioreactor, to promote new cell adhesion, growth, and 
integration.
Creating a clear scaffold for the reintroduction of stem 
cells is performed by coronary perfusion of a decellularizing 
agent. The choice of agent affects the level of antigenicity 
of the remaining tissue and its tensile strength, and an ideal 
decellularization process would remove antigenic material 
and preserve structural integrity.157 Detergents, organic 
 solvents, and enzyme solutions that solubilize cell mem-
branes can weaken the ECM. More vigorous agents, includ-
ing ionic detergents such as sodium dodecyl sulfate (SDS) 
or enzymatic digestion with trypsin, are effective at remov-
ing antigens but can cause degradation of collagen.158,159 
A  gentler decellularization technique uses hypotonic saline 
to osmotically eliminate cells, but this can leave behind some 
antigenic material.160
SDS was used to decellularize a ventricular porcine myo-
cardium, processed into hemocompatible and biocompatible 
hydrogels, and then injected into a porcine model with MI.161 
A reduction in fibrosis, lack of thrombogenicity, and growth 
of cardiac muscles were observed. This was the first time that 
such percutaneous delivery of ECM using a transendocardial 
approach was carried out.162 Recent decellularization with 
SDS perfusion has been found successful in small animal 
organs and whole organs.155 With these promising results, 
such porcine heart models are being gradually translated to 
clinical applications.142,163
The choice of allogeneic or xenogeneic organ for decellular-
ization can be difficult. Allogeneic hearts are size-appropriate 
and most structurally compatible for implantation. They are a 
limited resource and have human antigens, which can be rec-
ognized readily by immune defenses, and can transmit disease 
within the same species. Meanwhile, xenogeneic hearts have 
lesser degrees of anatomical fit but are an abundant resource 
and cause less inter-species disease transmission. Porcine 
hearts in particular are favored for a xenogeneic scaffold.164 
Glutaraldehyde can be used to prevent acute immune rejec-
tion of the xenogeneic graft by cross-linking proteins, making 
them unrecognizable to host immune defenses, but delayed 
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Cardiac tissue engineering and regeneration using cell-based therapy
Ott et al pioneered the first bioengineered heart from 
decellularized organ matrix recellularized with stem cell 
infusion in 2008. The cellular components of rat hearts were 
dissolved in detergent solution, leaving an intact collagen 
skeleton. The hearts were injected with cardiac and vascular 
progenitor cells while supported in an organic reactor that 
simulated the preload and afterload of cardiac physiology. 
The result after 8 days of incubation was the detection of 
macroscopic contractions and overall pump strength equiva-
lent to 2% of the adult heart or 25% of the function of a 
16-week fetal heart.4
For larger models, porcine hearts have been decellular-
ized for re-injection with cells121,142,163 and a human heart 
has been tested as a scaffold for repopulation with human 
mesenchymal cells and murine cardiomyocytes.166
Decellularized injectable scaffolds and solubilized peri-
cardial gels are currently the two areas of research in which 
decellularization techniques have been found extremely 
helpful.134,167–172 Some of the other works include blends 
of natural and synthetic matrices to take advantage of both 
components.173 However, the technology of decellularization 
is still in its initial stage of development.
The future of this therapy will depend on achieving the 
correct combination of support structure and stem cells. One 
goal will be to provide a non-antigenic scaffold that will 
give durable, long-term support. Another will be to identify 
the mixture of cell lines that can provide contractility for 
adequate cardiac output and vascularity to sustain cardiac 
perfusion.
The major issue is the translation of basic research into 
clinical human use. Apart from its initial success, there have 
been reports of drawbacks with this method due to aging, 
incomplete decellularization,174 toxic effects, changes in bio-
chemical properties,137 and changes in the cell’s pathological 
immunogenicity.175–178 For instance, there has been a failure 
of clinically approved, tissue-engineered, decellularized 
porcine heart valves in pediatric patients; this was attributed 
to calcific depositions and incomplete decellularization of 
the implant.174
Scaffold-free constructs
Recent advancement in utilizing scaffolds as a substitute for 
the damaged ECM and supporting the viability and survival 
of cells used for cardiac tissue engineering is promising. 
However, the low cellular concentration inside the scaffold 
compared with the dense myocardial tissue of the native 
heart combined with the inflammatory reaction and fibrous 
tissue formation caused by scaffold degradation led to the 
consideration of building tissue engineering constructs with-
out the use of scaffolds.
Shimizu et al developed a cell sheet engineering tech-
nique to construct scaffold-free 3D cardiac tissue. Using a 
temperature-responsive culture surface, they were able to 
detach two-dimensional (2D) myocardial layers as an intact 
confluent sheets and stack them to produce a 3D cardiac 
construct.173
Cell sheets are obtained by using specialized cell-culture 
surfaces that are covalently grafted with the temperature-
responsive polymer poly(N-isopropylacrylamide).180 The 
surface is hydrophobic and allows attachment of cells when 
the temperature is 37°C; when the temperature is lowered 
to 32°C, the surface becomes hydrophilic and causes the 
detachment of the cultured cells as an intact layer without 
disrupting the deposited ECM or the cell-to-cell junction pro-
teins,181 both of which usually happen when using traditional 
enzymatic degradation substances such as trypsin.
When these 2D monolayers are stacked, they can rapidly 
attach and form cell-to-cell connections due to the presence 
of the intact deposited ECM. Shimizu et al also demonstrated 
that stacking monolayers of neonatal rat cardiomyocytes 
results in a spontaneously pulsating tissue with rapid elec-
trical coupling between the layers, which was supported by 
the observation of the rapid formation of functional gap 
junctions.182
Miyahara et al used this technique to generate a mono-
layer of adipose tissue-derived MSCs. Four weeks after induc-
ing MI in rats, they transplanted the 2D monolayer onto the 
scared myocardium. After transplantation, the sheet induced 
angiogenesis and grew to a thick striatum that included a few 
myocytes and prevented the progression of ventricular wall 
dilation and improved cardiac function.183
Similarly, Miyagawa et al transplanted 3D sheets of 
stacked monolayers of neonatal rat cardiomyocytes 2 weeks 
after inducing MI in rats. The 3D sheets became attached 
to the native myocardium, expressed connexin-43, showed 
angiogenesis and improved overall cardiac function.184
However, trying to apply such a method clinically is 
still challenging. The thickness limit for these 3D sheets 
was 80 µm, or three layers, as reported by Shimizu et al;182 
stacking more than three layers at once resulted in core tissue 
necrosis.185 Several methods have been proposed to increase 
the vascularity and thickness of these sheets. Coculture with 
ECs and treatment with VEGF and in vitro vascularization 
bioreactors, allowing for a multi-step stacking of three-layer 












































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1






Stem cell therapy is likely to be a fundamental treatment 
strategy in the not-too-distant future. Traditional medical and 
surgical therapies have reached a point of maximal clinical 
utility and new strategies are required to treat the large popula-
tion of patients with acute or chronic heart failure worldwide. 
Encouragingly, animal models have shown that stem cell 
therapy is safe and effective. As for the human clinical tri-
als, many have demonstrated the safety and feasibility of the 
therapy; others have shown no significant effect, but, on the 
other hand, the majority of those trials have shown a trend 
of positive effect, whether on EF or on scar regression. What 
is needed now is further clinical testing and refinement to 
achieve better, more reliable, and more reproducible benefits. 
Larger randomized controlled trials could demonstrate the 
utility of stem cell therapy and comparison of studies could 
help identify the cell lineages that are the most effective, 
whether alone or in combination. With continued support, the 
proposed paracrine effects of implanted stem cells on resi-
dent stem cells could also be elucidated. Possible stem cells 
signaling factors therapy alone can potentially be employed, 
removing the time and burden of autologous stem cell harvest, 
or the antigenicity and rejection of allogeneic implantation. 
The need for the treatment of ischemic and nonischemic heart 
failure is highly demanded. Therefore, ongoing advancement 
in this new frontier is expected to continue. More organized 
infrastructure and collaborative research efforts, guided by 
evidence-based information, and adequate funding are needed 
to meet the important challenges ahead. However, the holy 
grail of tissue engineering and regenerative medicine seems 
to progressively take shape and hold tremendous promise to 
benefit humankind and treat presently incurable diseases.
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